INS and type 1 diabetes mellitus: Concerning intra-individual variability, the insulin analogues IGlar and detemir already present lower within-subject variability than NPH, as demonstrated by Heise et al. in type 1 diabetes (T1D) patients distributed in three groups for receiving each one of these long-acting formulations (0.4 U/kg once daily on four identical study days) under euglycemic clamp conditions.